

Serena Guiducci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8484653/publications.pdf>

Version: 2024-02-01

180
papers

11,462
citations

50170

46
h-index

30848

102
g-index

182
all docs

182
docs citations

182
times ranked

10430
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	0.9	53
2	Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. <i>Rheumatology</i> , 2022, 61, SI56-SI64.	0.9	11
3	The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. <i>Clinical Rheumatology</i> , 2022, 41, 573-579.	1.0	9
4	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	1.0	12
5	Ultrasound evaluation of bowel vasculopathy in systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2022, 100, 62-68.	1.0	5
6	Early diagnosis of systemic sclerosis, where do we stand today?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1-3.	1.3	3
7	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	1
8	Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?. <i>Frontiers in Immunology</i> , 2022, 13, 887279.	2.2	2
9	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
10	Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis. <i>Diagnostics</i> , 2022, 12, 1696.	1.3	8
11	The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 241-246.	1.0	7
12	Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. <i>Clinical Rheumatology</i> , 2021, 40, 1903-1912.	1.0	12
13	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	0.9	15
14	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.5	160
15	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	0.9	20
16	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.3	5
17	Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 4508-4519.	0.9	16
18	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 90.	1.2	9

#	ARTICLE	IF	CITATIONS
19	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	2.2	25
20	The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by Sjögren's syndrome patients. <i>Rheumatology and Immunology Research</i> , 2021, 2, 113-119.	0.2	0
21	AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report. <i>Journal of Medical Virology</i> , 2021, 93, 5718-5720.	2.5	29
22	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110336.	1.2	6
23	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	2.5	9
24	OUP accepted manuscript. <i>Rheumatology</i> , 2021, , .	0.9	0
25	Ultrasound in the diagnosis of morphea profunda and its complications: incarcerated digital extensor tendons. <i>Rheumatology</i> , 2021, , .	0.9	0
26	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	2.2	42
27	One year in review 2021: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 3-12.	0.4	1
28	One year in review 2021: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.4	25
29	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2020, 47, 881-887.	1.0	32
30	Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 6-20.	1.0	8
31	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). <i>Rheumatology</i> , 2020, 59, 1938-1948.	0.9	42
32	COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. <i>Clinical Rheumatology</i> , 2020, 39, 3195-3204.	1.0	105
33	Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 3645-3656.	0.9	10
34	Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. <i>Chest</i> , 2020, 158, 1515-1525.	0.4	50
35	The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091845.	1.2	13
36	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. <i>Clinical Rheumatology</i> , 2020, 39, 2043-2047.	1.0	27

#	ARTICLE	IF	CITATIONS
37	Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1310.	1.0	5
38	One year in review 2020: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 3-17.	0.4	6
39	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.5	31
40	Enthesopathy and involvement of synovio-enthesal complex in systemic sclerosis: an ultrasound pilot study. <i>Rheumatology</i> , 2019, 59, 580-585.	0.9	6
41	Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 1256.	1.0	11
42	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. <i>European Journal of Internal Medicine</i> , 2019, 70, 43-49.	1.0	7
43	Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	1.9	23
44	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
45	SAT0265â€¦DETERMINANTS OF RENAL RESISTIVE INDEX (RRI) AT RENAL ARTERY DOPPLER ULTRASOUND IN SYSTEMIC SCLEROSIS (SSC): MORE THAN GENERAL POPULATION FACTORS. , 2019, , .		0
46	FRI0325â€¦IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€œ A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
47	OPO239â€¦PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1
48	AB0369â€¦SAFETY, EFFICACY AND RETENTION RATE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) IN ASSOCIATION WITH DENOSUMAB: COMPARISON OF COMBINATION AND MONO-THERAPY REGIMENS. , 2019, , .		0
49	AB0639â€¦PREDICTION OF MAJOR VASCULAR COMPLICATIONS IN SYSTEMIC SCLEROSIS (SSC). , 2019, , .		0
50	FRI0314â€¦SENSITIVITY TO CHANGE AND RESPONSIVENESS TO TREATMENT OF RENAL RESISTIVE INDEX (IRR) IN SYSTEMIC SCLEROSIS (SSC). , 2019, , .		0
51	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
52	SAT0253â€¦PROGNOSTIC VALUE OF CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS. , 2019, , .		0
53	SAT0266â€¦DIGITAL ULCER (DU) AND VENTRICULAR ARRHYTHMIAS PREDICT THE LATE GADOLINIUM ENHANCEMENT (LGE) IN CARDIAC MAGNETIC RESONANCE (CMR) IN SYSTEMIC SCLEROSIS (SSC): PROPOSAL OF CANDIDATE RED FLAGS FOR EARLY REFERRAL. , 2019, , .		0
54	OPO065â€¦THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	AB1355-HPRâ€¦A SYSTEMATIC LITERATURE REVIEW (SLR) ON NURSING SENSITIVE OUTCOMES IN SYSTEMIC SCLEROSIS (SSC). , 2019, , .		0
56	Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis. <i>Medicine (United States)</i> , 2019, 98, e16086.	0.4	4
57	Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6189.	1.8	9
58	Early Detection of Cardiac Involvement in Systemic Sclerosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 927-928.	2.3	30
59	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 603-608.	1.0	16
60	¹⁸ F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.5	17
61	Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 575-577.	0.5	8
62	A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 133-140.	0.4	0
63	One year in review 2019: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 3-14.	0.4	17
64	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
65	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
66	L'hydroxychloroquine et les atteintes articulaires dans la sclérodémie systémique: résultats préliminaires d'une étude prospective cas-témoin EUSTAR. <i>Revue Du Rhumatisme (Edition Française)</i> 2018, 85, 411-412.		0
67	A study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design. <i>Rheumatology</i> , 2018, 57, .	0.9	1
68	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , 2018, 9, 2045.	2.2	67
69	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 170-174.	1.0	27
70	Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1665-1674.	0.5	25
71	The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 135-141.	0.4	3
72	One year in review 2018: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 3-23.	0.4	14

#	ARTICLE	IF	CITATIONS
73	Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 924-934.	0.5	184
74	Proangiogenic effects of soluble $\hat{\pm}$ -Klotho on systemic sclerosis dermal microvascular endothelial cells. <i>Arthritis Research and Therapy</i> , 2017, 19, 27.	1.6	26
75	Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1190-1197.	1.0	25
76	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	1.6	63
77	Avascular bone necrosis: An underestimated complication of systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e3-e5.	1.6	7
78	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
79	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. <i>Joint Bone Spine</i> , 2017, 84, 747-748.	0.8	17
80	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. <i>Scientific Reports</i> , 2017, 7, 13293.	1.6	41
81	The $\hat{\epsilon}$ myth of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?. <i>Arthritis Research and Therapy</i> , 2017, 19, 162.	1.6	24
82	Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 1-10.	1.0	17
83	Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis. <i>PLoS ONE</i> , 2017, 12, e0183102.	1.1	32
84	One year in review 2016: spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 3-17.	0.4	27
85	Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 179-183.	0.4	5
86	One year in review 2017: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 3-20.	0.4	11
87	Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , 2016, 55, 1610-1614.	0.9	35
88	The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?. <i>Arthritis Research and Therapy</i> , 2016, 18, 36.	1.6	16
89	Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 474-478.	0.5	14
90	Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. <i>Journal of Rheumatology</i> , 2016, 43, 592-598.	1.0	17

#	ARTICLE	IF	CITATIONS
91	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
92	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.5	38
93	Recent updates in experimental protocols for endothelial cells. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 257-265.	1.0	3
94	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.4	20
95	Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 221.	1.6	26
96	Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide. <i>PLoS ONE</i> , 2015, 10, e0130166.	1.1	24
97	Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 74-80.	0.5	70
98	Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2015, 14, 314-322.	2.5	60
99	Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?. <i>Clinical Rheumatology</i> , 2015, 34, 795-798.	1.0	10
100	Upregulation of the α -N-Formyl Peptide Receptors in Scleroderma Fibroblasts Fosters the Switch to Myofibroblasts. <i>Journal of Immunology</i> , 2015, 194, 5161-5173.	0.4	33
101	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
102	Interstitial lung disease in systemic sclerosis: where do we stand?. <i>European Respiratory Review</i> , 2015, 24, 411-419.	3.0	90
103	Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 72-76.	0.9	57
104	Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 124-128.	0.5	60
105	Definition, Nomenclature, and Diagnostic Criteria. , 2015, , 13-19.		3
106	Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S148-52.	0.4	7
107	A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 253-262.	1.6	93
108	Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1700-1709.	0.5	72

#	ARTICLE	IF	CITATIONS
109	Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?. <i>Rheumatology</i> , 2014, 53, 975-987.	0.9	19
110	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.5	168
111	Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor- α Inhibitors Correlates with Increased Soluble Fas Levels. <i>Journal of Rheumatology</i> , 2014, 41, 1961-1965.	1.0	4
112	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	3.0	170
113	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
114	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
115	Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide. <i>Arthritis Research and Therapy</i> , 2013, 15, R90.	1.6	9
116	High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R69.	1.6	31
117	Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 247-257.	6.7	36
118	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
119	Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 390-395.	0.5	146
120	Early detection of myocardial and pulmonary oedema with MRI in an asymptomatic systemic sclerosis patient: successful recovery with pulse steroid. <i>Rheumatology</i> , 2013, 52, 1920-1921.	0.9	17
121	<i>Very early</i> versus <i>early</i> disease: the evolving definition of the "many faces"™ of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 319-321.	0.5	37
122	Immunosuppression for interstitial lung disease in systemic sclerosis. <i>European Respiratory Review</i> , 2013, 22, 236-243.	3.0	26
123	Increased plasma levels of the VEGF ₁₆₅ splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1425-1427.	0.5	39
124	Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 482-496.	1.6	134
125	Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1107-1109.	0.5	29
126	Treatment options in systemic sclerosis. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 851-865.	0.5	0

#	ARTICLE	IF	CITATIONS
127	A10.9â€¦Evidence for Progressive Reduction and Loss of Telocytes in the Dermal Cellular Network of Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A75.1-A75.	0.5	0
128	Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. <i>Arthritis Research and Therapy</i> , 2013, 15, R165.	1.6	18
129	Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. <i>Rheumatology</i> , 2012, 51, 1042-1048.	0.9	14
130	Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1064-1072.	0.5	95
131	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.5	33
132	RANK-RANKL-OPG in Hemophilic Arthropathy: From Clinical and Imaging Diagnosis to Histopathology. <i>Journal of Rheumatology</i> , 2012, 39, 1678-1686.	1.0	31
133	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63
134	â€œTo Be or Not To Be,â€•Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 589-598.	1.6	126
135	Very early diagnosis of systemic sclerosis. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 18-23.	0.3	3
136	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
137	Impaired Angiogenesis in Systemic Sclerosis: The Emerging Role of the Antiangiogenic VEGF165b Splice Variant. <i>Trends in Cardiovascular Medicine</i> , 2011, 21, 204-210.	2.3	53
138	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. <i>Annals of Internal Medicine</i> , 2011, 155, 65.	2.0	0
139	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
140	The origin of the myofibroblast in fibroproliferative vasculopathy: Does the endothelial cell steer the pathophysiology of systemic sclerosis?. <i>Arthritis and Rheumatism</i> , 2011, 63, 2164-2167.	6.7	22
141	Progressive Loss of Lymphatic Vessels in Skin of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 297-301.	1.0	26
142	Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1876-1878.	0.5	46
143	Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2011-2021.	0.5	75
144	Implantable Cardioverter Defibrillator Prevents Sudden Cardiac Death in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 1617-1621.	1.0	35

#	ARTICLE	IF	CITATIONS
145	Overexpression of VEGF ¹⁶⁵ b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis. <i>Circulation Research</i> , 2011, 109, e14-26.	2.0	148
146	Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1963-1967.	0.5	29
147	Microparticles and Kawasaki disease: a marker of vascular damage?. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S121-5.	0.4	8
148	Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis <i>versus</i> vasculogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1241-1254.	1.6	118
149	Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis?. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 555-564.	0.3	1
150	High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1140-1143.	0.5	82
151	Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. <i>Journal of Rheumatology</i> , 2010, 37, 1852-1857.	1.0	39
152	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 598-605.	0.5	97
153	Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. <i>Rheumatology</i> , 2010, 49, 1374-1382.	0.9	172
154	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	1.0	9
155	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. <i>Annals of Internal Medicine</i> , 2010, 153, 650.	2.0	100
156	Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. <i>Rheumatology</i> , 2009, 48, 920-925.	0.9	31
157	The Role of Infections in the Immunopathogenesis of Systemic Sclerosis—Evidence from Serological Studies. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 627-632.	1.8	61
158	Stiff skin syndrome: evidence for an inflammation-independent fibrosis?. <i>Rheumatology</i> , 2009, 48, 849-852.	0.9	15
159	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. <i>Journal of Rheumatology</i> , 2009, 36, 1464-1469.	1.0	45
160	Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. <i>Arthritis and Rheumatism</i> , 2008, 58, 1226-1236.	6.7	11
161	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2845-2853.	6.7	91
162	Systemic sclerosis and infections. <i>Autoimmunity Reviews</i> , 2008, 8, 36-40.	2.5	77

#	ARTICLE	IF	CITATIONS
163	Musculoskeletal involvement in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2008, 22, 339-350.	1.4	46
164	Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. Nature Clinical Practice Rheumatology, 2008, 4, 288-289.	3.2	5
165	Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Annals of the Rheumatic Diseases, 2007, 66, 1305-1310.	0.5	28
166	TOPOISOMERASE-I (SCL-70) AUTOANTIBODIES. , 2007, , 231-238.		0
167	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Research and Therapy, 2007, 9, 301.	1.6	150
168	Vascular complications of scleroderma. Autoimmunity Reviews, 2007, 6, 520-523.	2.5	157
169	Flow-Mediated Vasodilation and Carotid Intima-Media Thickness in Systemic Sclerosis. Annals of the New York Academy of Sciences, 2007, 1108, 283-290.	1.8	70
170	Exercise Doppler Echocardiography Identifies Preclinic Asymptomatic Pulmonary Hypertension in Systemic Sclerosis. Annals of the New York Academy of Sciences, 2007, 1108, 291-304.	1.8	30
171	A model of anti-angiogenesis: differential transcriptome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Research and Therapy, 2006, 8, R115.	1.6	56
172	Angiotensin-Converting Enzyme in Systemic Sclerosis: From Endothelial Injury to a Genetic Polymorphism. Annals of the New York Academy of Sciences, 2006, 1069, 10-19.	1.8	8
173	Hemorheologic profile in systemic sclerosis: Role of NOS3 $\hat{\sim}$ 786T>C and 894G>T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease. Arthritis and Rheumatism, 2006, 54, 2263-2270.	6.7	14
174	Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis and Rheumatism, 2006, 54, 3022-3033.	6.7	64
175	The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis and Rheumatism, 2005, 52, 3618-3628.	6.7	55
176	Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis and Rheumatism, 2004, 50, 3275-3285.	6.7	118
177	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Research, 2002, 4, R11.	2.0	230
178	Activin, a Grape Seed-derived Proanthocyanidin Extract, Reduces Plasma Levels of Oxidative Stress and Adhesion Molecules (ICAM-1, VCAM-1 and E-selectin) in Systemic Sclerosis. Free Radical Research, 2002, 36, 819-825.	1.5	66
179	Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis and Rheumatism, 2001, 44, 2665-2678.	6.7	154
180	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. Clinical and Experimental Rheumatology, 0, , .	0.4	2